Literature DB >> 6772062

Mucormycosis.

.   

Abstract

The term mucormycosis encompasses a distinctive group of infections caused by fungi belonging to genera within the taxonomic order Mucorales, usually Rhizopus, Absidia, Mortierella, and Mucor. These fungi are widespread in nature, subsisting on decaying vegetation and diverse organic materials. Although the fungi and spores of Mucorales show minimal intrinsic pathogenicity toward normal persons, they can initiate aggressive and fulminant infections under certain clinical conditions. Ketoacidotic diabetics are predisposed to rhinocerebral mucormycosis, whereas patients with leukemia or lymphoma are susceptible to pulmonary or disseminated infections. These infections, which often result in devastating long-term sequelae for surviving patients, pose difficult diagnostic and therapeutic challenges.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6772062     DOI: 10.7326/0003-4819-93-1-93

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  34 in total

1.  Local application of antimycotics in mucormycosis cerebri: a case report.

Authors:  I Mohsenipour; M Schirmer; R Frank; F Geisen; E Semenitz; D zur Nedden; G Konwalinka
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-11       Impact factor: 10.154

2.  Three fatal cases of disseminated mucormycosis associated with respiratory distress syndrome and shock in patients with hematologic malignancies.

Authors:  F Agh; S Spanik; J Gyarfas; J Horváth; V Krcmery
Journal:  Infection       Date:  1992 Mar-Apr       Impact factor: 3.553

3.  Mucormycosis spondylodiscitis after lumbar disc puncture.

Authors:  Fei Chen; Guohua Lü; Yijun Kang; Zeming Ma; Chang Lu; Bin Wang; Jin Li; Jun Liu; Haisheng Li
Journal:  Eur Spine J       Date:  2005-11-18       Impact factor: 3.134

Review 4.  Mucor dimorphism.

Authors:  M Orlowski
Journal:  Microbiol Rev       Date:  1991-06

5.  Zygomycotic gangrenous cellulitis in a patient with non-insulin dependent diabetes mellitus.

Authors:  O Zimhony; E Israeli; S D Malnick; A Pansky; P Cohen; D Geltner
Journal:  West J Med       Date:  1998-03

6.  An amphotericin B-resistant case of rhinocerebral mucor mycosis.

Authors:  J Barnert; W Behr; H Reich
Journal:  Infection       Date:  1985 May-Jun       Impact factor: 3.553

Review 7.  Systemic zygomycosis.

Authors:  E W Benbow; R W Stoddart
Journal:  Postgrad Med J       Date:  1986-11       Impact factor: 2.401

8.  Sequential morphological changes in follow-up CT of pulmonary mucormycosis.

Authors:  Ji Yung Choo; Chang Min Park; Hyun-Ju Lee; Chang Hyun Lee; Jin Mo Goo; Jung-Gi Im
Journal:  Diagn Interv Radiol       Date:  2014 Jan-Feb       Impact factor: 2.630

9.  Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies.

Authors:  J R Boelaert; M de Locht; J Van Cutsem; V Kerrels; B Cantinieaux; A Verdonck; H W Van Landuyt; Y J Schneider
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

10.  Pulmonary invasive mucormycosis in a patient with secondary iron overload following deferoxamine therapy.

Authors:  Hector M Reyes; Eric J Tingle; Andrew Z Fenves; Jennifer Spiegel; Elizabeth C Burton
Journal:  Proc (Bayl Univ Med Cent)       Date:  2008-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.